













































































© Endocrine Society 2019. All rights reserved. For permissions, please e-mail: 
journals.permissions@oup.com. jc.2019-40040. See endocrine.org/publications for Accepted 
Manuscript disclaimer and additional information. 
Parathyroid hormone and plasma phosphate are predictors of 
soluble α-klotho levels in adults of European descent 
Nasser A. Dhayat1, Menno Pruijm2, Belen Ponte3, Daniel Ackermann1, Alexander Benedikt 
Leichtle4,5, Olivier Devuyst6, Georg Ehret7, Idris Guessous8, Antoinette Pechère-Bertschi9, 
Johanne Pastor10, Pierre-Yves Martin3, Michel Burnier2, Georg-Martin Fiedler4, Bruno Vogt1, 
Orson W. Moe10, Murielle Bochud11, *, Daniel G. Fuster1,*  
*Contributed equally 
1Department of Nephrology and Hypertension, Inselspital, Bern University Hospital, 
University of Bern, Switzerland, 2Nephrology Service, Lausanne University Hospital, 
Lausanne, Switzerland, 3Nephrology Service, Department of Specialties of Internal Medicine, 
Geneva University Hospital, Geneva, Switzerland, 4Department of Laboratory Medicine, 
Inselspital, Bern University Hospital, University of Bern, Switzerland, 5Insel Data Science 
Center, Inselspital, Bern University Hospital, University of Bern, Switzerland, 6Institute of 
Physiology, University of Zurich, 7Cardiology Service, Department of Specialties of Internal 
Medicine, Geneva University Hospital, Geneva, Switzerland, 8Division of Primary Care 
Medicine, Geneva University Hospital, Geneva, Switzerland, 9Endocrinology Service, 
Department of Specialties of Internal Medicine, Geneva University Hospital, Geneva, 
Switzerland, 10Charles and Jane Pak Center of Mineral Metabolism and Clinical Research, 
Department of Physiology and Department of Internal Medicine, University of Texas 
Southwestern Medical Center, Dallas, Texas, USA, 11Center for Primary Care and Public 
Health (Unisanté) , University of Lausanne, Lausanne, Switzerland. 
Corresponding author and person to whom reprint requests should be addressed: 
Daniel G. Fuster, Department of Nephrology and Hypertension, Inselspital, Bern University 
Hospital, University of Bern, Freiburgstrasse 15, 3010 Bern, Switzerland, Email: 





















Page 3 of 29 
 
Keywords: soluble α-klotho, parathyroid hormone, phosphate 
DISCLOSURE STATEMENT: DGF has served as a consultant for Otsuka Pharmaceuticals 
and received unrestricted research funding from Novartis, Abbvie and Otsuka Pharmaceuticals. 
OWM served on Scientific or Medical Advisory Boards for Allena, Ardelyx, Genzyme-Sanofi, 





















Page 4 of 29 
 
Abstract 
Context α-klotho is an integral membrane protein, that serves as a co-receptor for fibroblast 
growth factor 23 (FGF23) in conjunction with cognate fibroblast growth factor receptors. 
Proteolytic cleavage sheds the ectodomain of α-klotho (soluble α-klotho) as an endocrine 
substance into blood, urine and cerebrospinal fluid. 
Objective To study the relationship of soluble α-klotho to mineral metabolism in the general 
population with mainly preserved kidney function. 
Design Cross-sectional analysis of the associations between soluble α-klotho with laboratory 
markers of markers of mineral metabolism in a population-based cohort. 
Setting Three centers in Switzerland including 1128 participants. 
Measures Soluble full-length α-klotho levels by a specific immunoassay and markers of 
mineral metabolism. 
Results The median serum level of soluble α-klotho was 15.0 pmol/L. Multivariable analyses 
using α-klotho as outcome variable revealed a sex-by-parathyroid hormone (PTH) interaction: 
In men, PTH was positively associated with α-klotho levels whereas this association was 
negative in women. Plasma phosphate associated with soluble α-klotho levels in an age-
dependent manner, changing from a positive association in young adults gradually to a negative 
association in the elderly. The decline of 1,25 (OH)2 vitamin D3 levels in parallel to the gradual 
impairment of kidney function was greatly attenuated in the setting of high circulating soluble 
α-klotho levels. 
Conclusions Soluble α-klotho level is associated with plasma phosphate in an age-dependent 
manner and with PTH in a sex-dependent manner. Furthermore, our data reveal soluble α-klotho 
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INTRODUCTION 
α-klotho is a single-pass transmembrane protein that is expressed in renal tubular epithelia, the 
parathyroid gland, the brain choroid plexus and the hippocampus. The integral membrane 
protein α-klotho serves as a scaffold with cognate fibroblast growth factor receptors (FGFRs), 
including FGFR1c, FGFR3c and FGFR4, and is critical for FGF23 action in FGF23 target 
tissues (1). Loss of α-klotho in mice results in premature multi-organ failure with reduced 
lifespan, increased blood pressure due to impaired endothelium-mediated vasodilation and 
multiple organ defects such as ectopic calcifications, osteoporosis, hypogonadism, 
neurodegeneration and lung parenchymal degenerative changes (2). Alpha-klotho-deficient 
mice exhibit hypercalcemia, hyperphosphatemia and increased 1,25-(OH)2 vitamin D levels. 
The phenotype of α-klotho deficient mice is virtually identical to FGF23 null mice, indicating 
that both act along similar pathways (3). In humans, homozygous loss-of-function mutations in 
α-klotho cause a syndrome resembling familial tumoral calcinosis, characterized by ectopic 
calcifications and severe hypercalcemia and hyperphosphatemia (4). 
Proteolytic cleavage of the transmembrane α-klotho by members 10 and 17 of the A desintegrin 
and metalloproteinase (ADAM) family, and the beta-secretase beta-APP-1, sheds the 
ectodomain of α-klotho (soluble α-klotho) as an endocrine substance into blood, urine and 
cerebrospinal fluid (5, 6). Circulating soluble α-klotho is mainly of renal origin (7, 8). Soluble 
α-Klotho lacks FGFR co-receptor activity and can act independently of FGF23 through Wnt, 
growth factor and TGF-β pathways, possibly by modulation of lipid raft signaling, as well as 
direct action on renal phosphate and calcium transporters via intrinsic glycosidase activity (9-
13); an enzymatic activity that is debated (14). The same study provided an alternative view by 
demonstrating that soluble α-klotho in very high concentrations in vitro can serve as a co-
receptor for FGF23 in conjunction with FGFRs suggesting that the pleiotropic effects of soluble 
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Reduced renal α-klotho expression and reduced circulating α-klotho levels were found in acute 
and chronic kidney disease models, hormonal hypertension, metabolic syndrome and diabetes 
in rodents (15-17). Low α-klotho is not a mere biomarker but pathogenic as restoration of α-
klotho in experimental rodent chronic kidney disease (CKD) models ameliorated kidney disease 
and extra-renal complications in rodents (16, 18). This hoists the significance of α-klotho 
deficiency in CKD from diagnostic and prognostic to therapeutic.  
Relatively little is known about the factors that regulate circulating α-klotho levels in humans 
and the available data are conflicting (17, 19-27). Current commercial ELISAs employed for 
the determination of soluble α-klotho in humans have certain limitations, including cross-
reactivity with other serum proteins, loss of efficiency after repeated freeze-thawing of samples, 
loss of sensitivity with vintage of storage resulting in discrepant results with fresh versus stored 
samples (28). These limitations likely explain some of the discrepancies reported in the 
literature. An assay for α-klotho in serum and urine was developed and characterized, based on 
an immunoprecipitation-immunoblotting (IP-IB) assay, that overcomes a number of the 
limitations of the commercial ELISAs (28). This assay measures the full-length 130 kDa, 
secreted form of α-klotho specifically. Using this assay, we conducted a cross-sectional analysis 
in a large, multicenter, opulation-based cohort to investigate the association of mineral 
metabolism markers with serum α-klotho levels (29). 
 
MATERIALS AND METHODS 
Study population 
SKIPOGH is a multicenter family-based cross-sectional study exploring the role of genes and 
kidney hemodynamics in blood pressure regulation and kidney function in the general adult 
population (29). Inclusion criteria were: (1) a minimum age of 18 years; (2) European ancestry; 
(3) having at least one and ideally three first-degree family members willing to participate; and 
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and was approved by the institutional ethical committees of each participating University 
hospital. Of a total of 1128 SKIPOGH participants, 118 participants were excluded from the 
final analysis for the following reasons: (1) primary hyperparathyroidism or history of 
parathyroidectomy (n=2); (2) chronic liver disease (n=1); (3) active malignant diseases (n=10); 
(4) pregnancy (n=1); (5) intake of the following drugs: over-the-counter or prescribed calcium 
and/or vitamin D supplements (n=22), bisphosphonates (n=2), glucocorticoids or 
mineralocorticoids (n=5), antiepileptics (n=2), loop diuretics (n=6), thiazide diuretics (n=63), 
potassium sparing diuretics (n=5), and desmopressin (n=1). Of the remaining 1010 participants, 
98 serum samples were lacking for the analysis of α-klotho, leaving 912 participants from 269 
distinct families and three study centers available for the final analysis. 
 
Data collection and measurements 
Absolute urinary creatinine excretion was used as the criterion for completeness of 24-hour 
urine collections, using recently published data from the cross-sectional Swiss Salt Study (SSS) 
(29, 30). Urine collections were considered as complete if the total 24-hour creatinine excretion 
was within centiles 2.5 and 97.5. Fasting morning electrolytes and serum creatinine were 
measured by standard clinical laboratory methods in each center. Plasma FGF23, PTH, 25-
(OH) vitamin D3 and 1,25-(OH)2 vitamin D3 were determined centrally for all study participants 
as single measurements. Plasma FGF23 was measured in the laboratory of TECOmedical AG 
(Sissach, Switzerland) by the second generation C-terminal assay (Immutopics, San Clemente, 
CA) (29, 31). Lower detection limit of the assay is 1.5 RU/ml, intra- and inter-assay coefficients 
of variation are 1.4-2.4% and 2.4-4.7%, respectively. Plasma PTH, 25-(OH) vitamin D3 and 
1,25-(OH)2 vitamin D3 were measured in the Center of Laboratory Medicine, Inselspital, Berne: 
Plasma intact PTH by electrochemiluminescence immunoassay (ECLIA) on a Roche Modular 
E170 (Roche Diagnostics AG, Rotkreuz, Switzerland), plasma 25-(OH) vitamin D3 by a direct, 
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S.p.A., Saluggia (VC), Italy) and plasma 1,25-(OH)2 vitamin D3 by a competitive enzym-
immunoassay on a Multilabel Counter Victor 3 (PerkinElmer, Inc., Waltham, USA). Intra- and 
inter-assay coefficients of variation are 1.1-2.0% and 2.5-3.4% for plasma PTH, 4.1-5.8% and 
6.6-7.1% for plasma 25-(OH) vitamin D3 and <8 - <10% for plasma 1,25-(OH)2 vitamin D3 
respectively. 
For the determination of soluble α-klotho, we used serum samples obtained while fasting in the 
morning, frozen the day of blood draw and kept at – 80 °C thereafter. All serum samples were 
thawed only once, for determination of serum α-klotho levels. Soluble serum α-klotho levels 
by a quantitative immunoprecipitation – immunoblotting assay, as described in detail (28, 32). 
Briefly, 50 μL of serum were diluted with KRH buffer [25 mM HEPES–NaOH (pH 7.4), 120 
mM NaCl, 5 mM KCl, 1.2 mM MgSO4, 1.3 mM CaCl2, 1.3 mM KH2PO4] to a final volume of 
0.5 mL and incubated overnight at 4°C with 2 μg of Fab 48 (alias sb106), which recognizes 
both HEK293 cell–expressed human full-length membrane α-klotho as well as the soluble α-
klotho ectodomain. Fab sb48-FLAG - α-klotho complexes were immunoprecipitated with 
ANTI-FLAG® M2 Affinity Agarose Gel beads (Sigma-Aldrich, St-Louis Mi.), fractionated by 
SDS–PAGE and transferred to nitrocellulose membranes. Immunoblotting with anti-α klotho 
antibody KM2076 (Transgenic Inc., Kobe, Japan) was used to detect the soluble α-klotho 
ectodomain (~130 kDa). The 130 kDa bands were scanned, and density was compared with 
internal standards of known amounts of α-klotho (murine klotho isoform, obtained from a CHO 
cell line that stably expresses the full-length klotho isoform 1, gift from Kyowa Hakko Kogyo 
Co. Ltd. (33)) to calculate final α-klotho concentration in individual serum samples. Intra- and 
inter-assay coefficients of the assay are 8-18% and 4.8-16.6 %, respectively. 
The creatinine-based CKD-EPI 2009 equation was used to estimate the glomerular filtration 
rate (eGFRcr) (34). Tubular maximum reabsorption of phosphorus per glomerular filtration rate 
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Statistical analysis 
All statistical analyses were conducted using the R software, version 3.2.2 (37). The shape of 
the distribution of each continuous variable was visually inspected and square-root-, log- or 
inverse-transformations were applied to better approximate a normal distribution of the 
residuals for statistical analyses. All statistical tests were two-sided and a P value <0.05 was 
considered statistically significant, including for two-way interaction analyses.  
We assessed the univariable association between the linear and quadratic terms of explanatory 
variables of interest with square-root transformed soluble α-klotho as outcome variable, 
determined as an appropriate transformation. All models were calculated by mixed-effects 
linear regression with day of blood sampling and family nested within center as the random 
effect structure. Quadratic terms of the explanatory variables were not found to be significantly 
associated with the outcome variable. All models were then extended to multivariable analyses 
by adding the following explanatory variables and their interaction terms as fixed effects: sex, 
age, BMI, eGFRcr, study center, and serum sample freezing time. Fixed effects and statistically 
significant interaction terms were kept in the final models, while keeping hierarchically sound 
models. Models were validated by graphical analysis for homogeneity of variance, normality 
of residuals and highly influential observations. Additional regression analyses were conducted 
exploring the univariate association between soluble α-klotho, as explanatory variable, with 
transformed laboratory parameters of mineral metabolism as outcome variables while keeping 
the random effect structure in all models. Multivariable models were derived thereof by adding 
sex, age, body mass index, eGFRcr, study center, and the serum sample freezing time to soluble 
α-klotho (as the explanatory variable of interest). All models were created with continuous 
explanatory variables mean centered at zero to minimize collinearity problems. Selected 
multivariable regression models were plotted to illustrate the relationship between the 
explanatory variable of interest with the outcome variable while holding the effect of all other 
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that these plots provide no confidence bands as the created models does not offer predictions 





















Page 11 of 29 
 
RESULTS 
Characteristics of the study population 
Characteristics of the study population are shown in Table 1. Participants were 18 – 90 years 
old, with a median age of 45.7 years (25th-75th percentile 30.2-58.0 years), and 52.3% were 
women. Median eGFRcr (glomerular filtration rate estimated based on creatinine equation 
CKD-EPI 2009) was 98.4 mL/min per 1.73 m2. Of note, only 2.3% of study participants had an 
eGFRcr < 60 mL/min per 1.73 m2. The distribution of soluble α-klotho levels was right skewed 
with a median serum level of 15.0 pmol/L (25th-75th percentile 10.0-21.0 pmol/L) (Fig. 1A, C). 
After square root transformation, soluble α-klotho residual values displayed a near normal 
distribution, both in the entire study population but also within both sex subgroups (Fig. 1B, 
D). Soluble α-klotho levels were slightly higher in women (median 15.3 pmol/L, 25th-75th 
percentile 10.0-22.0 pmol/L) than in men (median 13.9 pmol/l, 25th-75th percentile 9.9-20.0; P 
= 0.018, Welch t-test, Fig. 1E), and higher in individuals aged ≤30 years (median 16.0 pmol/l, 
25th-75th percentile 10.2-22.0) than in those aged ≥60 years old (median 14.0 pmol/l, 25th-75th 
percentile 9.6-20.0; P = 0.028, Welch t-test). In a simple univariable linear regression analysis 
higher soluble α-klotho levels were found at higher eGFRcr (: 0.0063, P = 0.00096, Fig. 1F). 
 
Association analyses with soluble α-klotho as outcome variable 
We first performed association analyses between the population characteristics as explanatory 
(i.e. independent) variables and square root transformed soluble α-klotho as outcome (i.e. 
dependent) variable. All models were calculated by mixed-effects linear regression (Table 2). 
In univariable analyses, positive correlates of soluble α-klotho were female sex (: 0.1507, P = 
0.0035), eGFRcr (: 0.0044, P = 0.0051) and plasma calcium (: 0.6672, P = 0.042), whereas 
age (: -0.0038, P = 0.015) and BMI (: -0.0172, P = 0.01) were negatively associated with 
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linear regression using indicated predictor variables and soluble α-klotho as outcome variable. 
As shown in Table 2, multivariable analyses revealed a significant sex-by PTH interaction for 
their association with soluble α-klotho (: -0.0111, P = 0.0045). Visualization of this interaction 
in Fig. 2A reveals that the association of PTH with soluble α-klotho levels is sex-specific, being 
positive in men and negative in women. Additionally, we also discovered a significant age-
dependent association between plasma phosphate and soluble α-klotho (: -0.0220, P = 0.011). 
As depicted in Fig. 2B, in young adults the association is positive but then becomes 
progressively negative with increasing age. All other associations with soluble α-klotho as 
outcome variable remained no longer significant after multivariable adjustment. 
 
Association analyses with soluble α-klotho as predictor variable 
We then performed association analyses with soluble serum α-klotho as predictor variable and 
laboratory parameters of calcium-phosphate metabolism as outcome variables using mixed-
effects linear regression (Table 3). In univariable analyses eGFRcr (: 3.47, P = 0.0018) and 
plasma calcium (: 0.0002, P = 0.036) were positively associated with soluble α-klotho. In 
multivariable regression analyses (Table 3), soluble α-klotho displayed a significant interaction 
with eGFRcr for the association with 1,25 (OH)2 vitamin D3 (: -0.0009, P = 0.029), i.e. the 
positive association of eGFRcr with 1,25 (OH)2 vitamin D3 was significantly influenced by 
circulating α-klotho levels (Fig. 3A). Similarly, we observed an inverse association of body 
mass index with plasma phosphate (: 0.0004, P = 0.011) that was dependent on circulating α-
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DISCUSSION 
We quantified soluble α-klotho levels using a specific IP-IB immunoassay in a well-
characterized population-based sample of individuals with largely preserved renal function. Our 
analysis revealed levels of circulating α-klotho in serum in the double digit picomolar range 
(median 15 pmol/L) – same order of magnitude as what has been reported previously with this 
assay (28). In univariable analyses, we observed several significant associations of eGFR and 
mineral metabolism markers with soluble α-klotho levels, which partially corroborate with 
previous findings (23, 26, 39-41). In contrast to previous small studies, the large data set 
enabled us to adjust for several potential confounders in multivariable analysis. We found a 
sex-specific association of α-klotho with PTH in the general adult population, with a negative 
association in women and a positive one in men. In mice, androgens increase and estrogens 
decrease α-klotho mRNA and protein expression in the kidney (42, 43), but to our knowledge, 
the impact of sex hormones on soluble α-klotho has not been studied in rodents or humans.  
Parathyroid glands express α-klotho, but mice with parathyroid-specific deletion of α-klotho 
have a normal phenotype and survival, normal serum PTH and calcium and unaltered 
expression of the PTH gene in parathyroid tissue (44). However, combined deletion of α-klotho 
and the calcium-sensing receptor (CASR) in parathyroid glands results in significantly higher 
serum PTH, FGF23, and 1,25 (OH)2 vitamin D3 levels compared to mice with a parathyroid-
specific deletion of the CASR alone, indicating that α-klotho expressed in the parathyroid gland 
is a negative regulator of PTH synthesis that works synergistically with CaSR (45). Another 
model indicates that α-klotho directly interacts with the PTH receptor and thereby attenuates 
PTH signaling in target tissues (46). While target organ resistance to PTH would be consistent 
with a positive association of circulating α-klotho levels with PTH, an inverse correlation 
between soluble α-klotho and PTH would be expected if α-klotho acts as a suppressor of PTH 
secretion in vivo. Our data indicate that the association of PTH and α-klotho is complex and 
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cannot be answered through cross-sectional analyses like our study and remains to be tested 
using longitudinal data.  
The lack of an association with GFR contrasts a previous study in a small group of healthy 
volunteers and patients with much more severe reductions of GFR (CKD stages I-V) employing 
the same immunoassay which concluded that there was a gradual decrease of α-klotho in serum 
with declining GFR (28). Importantly, there is considerable overlap of serum α-klotho levels 
between healthy volunteers and CKD stages I and II. Also, due to the small number of 
individuals, adjustment for potential confounders was not possible in that study. In univariable 
analyses, we similarly observed a significant association of GFR with soluble α-klotho even 
within the small and mostly normal range of GFR, but the association was not significant after 
multivariable adjustment. The most important point is that the individuals in our cohort had 
normal renal function, and only an extremely small fraction (2.3%) had a GFR < 60 mL/min 
per 1.73m2. Hence, it is entirely possible that circulating α-klotho levels indeed decline 
marginally in CKD I and II but can be buried with the other determinants, but in CKD stages 
III, IV and V, the association remains significant even after adjustment for multiple 
confounders.  
As expected for a circulating factor involved in phosphate homeostasis, plasma phosphate 
correlated with circulating α-klotho levels in our cohort (8). The association was strongly age-
dependent (positive in young and negative in older adults) and not paralleled by correlations of 
soluble α-klotho levels with TmP/GFR or fractional excretion of phosphate. Thus, soluble α-
klotho-mediated differences in renal phosphate handling are unlikely to account for this 
association. Rather the result suggests that plasma phosphate influences soluble α-klotho levels, 
possibly by affecting its synthesis in the kidney. Phosphate loading in rodents consistently 
reduced circulating serum α-klotho but this was not observed in humans (47). A recent 
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volunteers under a high phosphate diet (32). Alternatively, soluble α-klotho may affect extra-
renal handling of phosphate in bone or gut in an age-dependent manner. 
In a previous analysis of this cohort, we discovered that the decline of 1,25 (OH)2 vitamin D3  
with falling GFR is closely paralleled and significantly associated by a rise in FGF23, a negative 
regulator of 1,25 (OH)2 vitamin D3 synthesis in the proximal tubule (29). Our data now 
demonstrate that the well-known GFR dependence of 1,25 (OH)2 vitamin D3 levels is 
significantly influenced by soluble α-klotho. In the setting of high soluble α-klotho, the GFR-
dependent decline of 1,25 (OH)2 vitamin D3 is greatly attenuated. This finding suggests that α-
klotho antagonizes the FGF23-mediated downregulation of 1,25 (OH)2 vitamin D3 in early 
CKD. Since soluble α-klotho and 1,25 (OH)2 vitamin D3 are both kidney-tubule derived 
substances, the finding could also be explained by differences in tubular function at an 
individual level of GFR: Preserved tubular function despite reduction in GFR would be 
associated with normal or near normal circulating α-klotho and 1,25 (OH)2 vitamin D3 levels. 
On the other hand, circulating α-klotho and 1,25 (OH)2 vitamin D3 levels maybe reduced due 
to tubular dysfunction despite preserved GFR. Quantification of circulating α-klotho in 
different CKD subgroups (predominant tubule-interstitial versus isolated glomerular disease) 
could shed more light on the interaction between α-klotho and 1,25 (OH)2 vitamin D3. 
Ultimately, however, interventional studies will be needed to understand the underlying 
mechanisms. 
Our study reproduces the previous observation of an inverse association of plasma phosphate 
with BMI (48). Both increased PTH and FGF23 levels have been reported in individuals with 
increased fat mass and adiposity (49-51). Our results indicate that the negative association of 
BMI with plasma phosphate is modulated by circulating α-klotho, possibly by either affecting 
PTH / FGF23 signalling at target organs or alternatively by altering PTH / FGF23 secretion. 
Our study has several limitations. The cross-sectional design only allows to infer associations 
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markers were available. In addition, while the IB-IP assay is very specific, it is not as 
quantitative than ELISA. Hence, it is possible that we missed factors weakly associated with 
soluble α-klotho in the current study.  
In summary, using a specific novel immunoassay for soluble α-klotho, our study reveals that 
plasma phosphate - in an age-dependent manner - and parathyroid hormone - in a sex-dependent 
manner - are associated with soluble α-klotho levels in humans. Furthermore, our data reveal 
soluble α-klotho as a modulator of 1,25 (OH)2 vitamin D3 levels in individuals with preserved 
renal function. 
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Figure 1. Distribution of soluble serum α-klotho in study participants. Panels A) – D) show 
density plots (y-axes) representing the probability density function for the kernel density 
estimation. In addition, histograms corresponding to frequencies are overlaid. A) Kernel density 
plots of soluble α-klotho serum levels (pmol/L) in entire study population. B) Distribution after 
square root transformation in entire study population. C) Kernel density plots of soluble α-
klotho serum levels separated by sex (men: blue, women: red). D) Distribution after square root 
transformation separated by sex (men: blue, women: red). E) Soluble α-klotho levels are higher 
in women (median 15.3 pmol/L, 25th-75th percentile 10.0-22.0 pmol/L) than men (median 13.9 
pmol/L, 25th-75th percentile 9.9-20.0; P = 0.018). F) Linear regression function of the 
associations of eGFRcr with square root transformed soluble serum α-klotho. The shadowed 
area represents the 95% confidence interval of the regression line. 
Figure 2. Association of PTH and plasma phosphate with soluble serum α-klotho. 
Multivariable regression models in Table 2 are visualized to illustrate the relationship between 
the explanatory variable of interest while holding the effect of all other covariables in the model 
constant. Solid lines represent regression lines. A) Association of PTH with soluble serum α-
klotho depending on sex. B) Association of plasma phosphate with soluble serum α-klotho 
depending on age. Study participants were divided into three equal sized groups belonging to 
the nearest class of age. 
Figure 3. Influence of soluble serum α-klotho on the association of eGFRcr with 1,25-OH-
Vitamin D3 and on the association of body mass index with plasma phosphate. 
Multivariable regression models in Table 3 are visualized to illustrate the relationship between 
the explanatory variable of interest while holding the effect of all other covariables in the model 
constant. Solid lines represent regression lines. A) Influence of soluble serum α-klotho on the 
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the association of body mass index with plasma phosphate. Study participants were divided into 
three equal sized groups belonging to the nearest class of soluble serum α-klotho levels. 
Table 1. Participants’ characteristics. Categorical variables are described by number of 
participants N (%), continuous variables are described by their mean±standard deviation (SD) 
and range or by their median;25th-75th percentile and range. Abbreviations: eGFRcr: glomerular 
filtration rate estimated creatinine Equation CKD-EPI 2009; BSA: body surface area, FGF23: 
fibroblast growth factor 23, PTH: parathyroid hormone, RU: relative unit. 
 
Table 2. Associations between predictor variables of interest with square-root 
transformed serum soluble α-klotho. For each predictor variable the results of an univariable 
and of a multivariable model are shown. Number of participants (N), beta coefficients (β), 95% 
confidence intervals (95% CI) and P values are indicated for the predictor variables of interest 
and in multivariable models also for significant interactions. 
 
Table 3. Associations between the predictor variable serum soluble α-klotho with 
laboratory parameters of calcium-phosphate metabolism. For each outcome variable the 
results of an univariable and of a multivariable model are shown. Number of participants (N), 
beta coefficients (β), 95% confidence intervals (95% CI) and P values are indicated for serum 
soluble α-klotho in univariable models and in multivariable models also for significant 





























Women, N (%) 912 477 (52.3)  
Age, y 912 45.7;30.2-58 18-90 
Body mass index, kg/m2 911 24;21.6-27.1 15.6-45.8 
eGFRcr, ml/min per 1.73m2 BSA 906 98.4;87.2-110 38.1-151 
  38-60 21 2.3%  
  60-70 42 4.6%  
  70-80 73 8.1%  
  80-90 136 15%  
  90-100 215 23.7%  
  100-110 194 21.4%  
  110-120 130 14.3%  
  120-130 74 8.2%  
  130-151 21 2.3%  
Soluble α-klotho, pmol/L 912 15;10-21 1.8-51.2 
PTH, pg/ml 909 36.9;29.6-45 8.8-108 
25-OH-Vitamin D3, nmol/L 908 47;34-62 5.5-163 
1,25-(OH)2 Vitamin D3, pmol/L 846 92;70-116 5.5-217 
FGF23, RU/ml 912 78.6;63-103 18-1078 
Phosphate plasma, mmol/L 904 1.04±0.166 0.55-1.66 
Calcium plasma, mmol/L 905 2.33;2.27-2.38 2.05-2.69 
Phosphate urine mmol/24h 890 25.3;20.2-31.9 2.77-101 
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Table 2. 
  Univariable Models   Multivariable Models 
Predictor variable N β 95% CI P value   N β 95% CI P value 
Age, y 912 -0.0038 -0.0068 to -0.0007 0.015   905 -0.0009 -0.00560.0038 0.70 
Sex, women 912 0.1507 0.0484-0.2534 0.0035   905 0.1620 0.0586-0.2669 0.0021 
BMI, kg/m2 911 -0.0172 -0.0303 to -0.0041 0.010   905 -0.0084 -0.022-0.0051 0.22 
eGFRcr, mL/min per 1.73m2 BSA 906 0.0044 0.0013-0.0075 0.0051   905 0.0024 -0.0022-0.007 0.31 
PTH, pg/mL 909 -0.0032 -0.0074-0.001 0.13   902 0.0063 0.0001-0.0125 0.049 
  interaction with sex             -0.0111 -0.0188 to -0.0035 0.0045 
  sex, women in the model       0.1697 0.2814-0.9137 0.00129 
25-OH-Vitamin D3, nmol/L 908 0.0022 -0.0004-0.0049 0.099   901 0.0014 -0.0013-0.004 0.32 
1,25-(OH)2 Vitamin D3, pmol/L 846 0.0000 -0.0017-0.0018 0.99   840 -0.0006 -0.0023-0.0012 0.55 
FGF23, RU/mL 912 0.0001 -0.0005-0.0008 0.69   905 0.0002 -0.0005-0.0008 0.64 
Phosphate plasma, mmol/L 904 0.0702 -0.2671-0.4056 0.68   903 -0.0648 -0.4120-0.2797 0.71 
  interaction with age             -0.0220 -0.0387 to -0.0050 0.011 
  age in the model       -0.0007 -0.0054-0.0040 0.76 
Calcium, mmol/L 905 0.6672 0.0265-1.3091 0.042   904 0.3957 -0.2358-1.0263 0.22 
Phosphate urine, mmol/24h 890 -0.0035 -0.009-0.002 0.21   883 -0.0005 -0.0067-0.0057 0.87 
Fractional excretion of phosphate, % 881 -0.0030 -0.0146-0.0086 0.61   880 0.0053 -0.008-0.0186 0.44 
TmP/GFR, mmol/L 881 0.1165 -0.1643-0.3957 0.41   880 -0.0468 -0.3531-0.2571 0.76 
Calcium urine, mmol/24h 887 -0.0173 -0.0434-0.0086 0.19   880 -0.0068 -0.0326-0.019 0.61 
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Table 3.
  Univariable Models   Multivariable Models 
Outcome variable N β 95% CI P value   N β 95% CI P value 
eGFRcr, mL/min per 1.73m2 BSA 906 3.474 1.274-5.662 0.0018   905 0.8742 -0.7328-2.4849 0.29 
PTH, pg/mL 909 -0.0017 -0.0045-0.0012 0.26   902 0.0004 -0.0024-0.0032 0.80 
25-OH-Vitamin D3, nmol/L 908 0.0025 -0.0107-0.0158 0.71   901 -0.0022 -0.0162-0.0116 0.75 
1,25-(OH)2 Vitamin D3, pmol/L 846 -0.0073 -0.0227-0.0082 0.36   840 -0.0067  -0.0226-0.0092 0.41 
              -0.0009*1 -0.0017 to -0.0009*1 0.029*1 
       0.0889*2 -0.0006-0.0184*2 0.068*2 
FGF23, RU/mL 912 0.0010 -0.003-0.005 0.63   905 0.0014 -0.0029-0.0057 0.54 
Phosphate plasma, mmol/L 904 -0.0005 -0.0019-0.0009 0.49   903 -0.0005   -0.0019-0.0010 0.53 
              0.0004#1 0.0001-0.0006#1 0.011#1 
       -0.0043#2 -0.0068 to -0.0018#2 0.00066#2 
Calcium, mmol/L 905 0.0002 0-0.0003 0.036   904 0.0001 -0.0001-0.0002 0.35 
Phosphate urine, mmol/24h 890 -0.0028 -0.0106-0.0048 0.47   883 -0.0009 -0.0083-0.0065 0.81 
Fractional excretion of phosphate, % 881 0.0003 -0.0051-0.0056 0.92   880 0.0012 -0.0037-0.0061 0.62 
TmP/GFR, mmol/L 881 -0.0002 -0.0011-0.0007 0.67   880 -0.0004 -0.0012-0.0005 0.40 
Calcium urine, mmol/24h 887 -0.0042 -0.0089-0.0004 0.075   880 -0.0012 -0.0061-0.0038 0.64 
Fractional excretion of calcium, % 876 -0.0024 -0.0056-0.0007 0.13   875 -0.0009 -0.0042-0.0025 0.61 
*1for interaction between soluble serum α-klotho and eGFRcr, *2for eGFRcr in the model 
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